Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-Release Injectable Buprenorphine in High Potency Synthetic Opioid Users
NCT06726200Phase 1Recruiting
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (2 arms). Primary endpoints: Percentage of Days Abstinent from Opioids at 4 weeks and Sustained Relapse at 4 weeks. Started Feb 2026; status: recruiting.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06726200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726200.